This analysis compares overall survival in metastatic non-small cell lung cancer patients treated with two immunotherapy regimens, suggesting pembrolizumab plus chemotherapy is more effective.
After MAIC and subsequent immunotherapy adjustments, pembrolizumab plus chemotherapy showed improved overall survival and progression-free survival versus cemiplimab plus chemotherapy in both non-squamous and squamous metastatic NSCLC at modest incremental cost.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: